Evolving Paradigms in Newly Diagnosed and R/R MM: Highlights from ASH 2024

home / around-the-practice / evolving-paradigms-in-newly-diagnosed-and-r-r-mm-highlights-from-ash-2024

Panelists discuss how emerging treatment strategies, including novel induction therapies, maintenance regimens, and bispecific antibodies, are reshaping the management of newly diagnosed and relapsed/refractory multiple myeloma, with insights from ASH 2024 data and ongoing trials.

Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM

EP. 1: Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM

Luciano Costa, MD, PhD;Bhagirathbhai Dholaria, MD;Carl Ola Landgren, MD, PhD ;Muhamed Baljevic, MD, FACP
December 17th 2024

Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.

Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations

EP. 2: Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations

Luciano Costa, MD, PhD;Bhagirathbhai Dholaria, MD;Carl Ola Landgren, MD, PhD ;Muhamed Baljevic, MD, FACP
January 2nd 2025

Panelists discuss the factors influencing the choice between isatuximab and daratumumab for induction therapy in transplant-eligible newly diagnosed multiple myeloma, as well as the role of dara-based quadruplet regimens as the standard of care and considerations for triplet regimens in specific patient populations.

AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM

EP. 3: AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM

Luciano Costa, MD, PhD;Bhagirathbhai Dholaria, MD;Carl Ola Landgren, MD, PhD ;Muhamed Baljevic, MD, FACP
January 14th 2025

Panelists discuss evolving approaches to maintenance therapy in newly diagnosed multiple myeloma, focusing on balancing survival benefits with tolerability. They also review the latest data from the AURIGA trial evaluating daratumumab and lenalidomide maintenance.